source
- Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomaliesRelay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vesse…
- Relay Therapeutics' zovegalisib meets efficacy endpoint in Phase 2 vascular anomalies trialRelay Therapeutics reported that its PI3Kα inhibitor zovegalisib achieved the predefined efficacy threshold in a Phase 2 study of a rare genetic vascular anomaly. The data readout exceeded Wall Str…